DRUG INTERACTIONS
- Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. Patients receiving oral anticoagulant therapy require close monitoring, especially when androgens are started or stopped.
- Oxyphenbutazone: Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.
- Insulin: In diabetic patients, the metabolic effects of androgens may decrease blood glucose and insulin requirements.
|
OVERDOSAGE
Numerous reports of ingestion of large doses of estrogen-containing oral contraceptives by young children indicate that serious ill effects do not occur. Overdosage of estrogen may cause nausea, and withdrawal bleeding may occur in females.
There have been no reports of acute overdosage with the androgens.
|
CONTRAINDICATIONS
Estrogens should not be used in women with any of the following conditions:
-
Known or suspected cancer of the breast except in appropriately selected patients being treated for metastatic disease.
-
Known or suspected estrogen-dependent neoplasia.
-
Known or suspected pregnancy (See BOX WARNINGS).
-
Undiagnosed abnormal genital bleeding.
-
Active thrombophlebitis or thromboembolic disorders.
-
A past history of thrombophlebitis, thrombosis, or thromboembolic disorders associated with previous estrogen use (except when in treatment of breast malignancy).
Methyltestosterone should not be used in:
-
The presence of severe liver damage.
-
Pregnancy and in breast-feeding mothers because of the possibility of masculinization of the female fetus or breast-fed infant.
|
|
Page last updated: 2006-03-07
|